Sign in Subscribe
BioMed

🧬 BioMed Pulse · 2026-07-05 02:02 UTC

BIOMED PULSE

July 5, 2026 | Your daily briefing on longevity, viruses, and new cures

⚡ TL;DR

The Bundibugyo virus Ebola outbreak in DRC and Uganda has now reached 1,460 confirmed cases and 452 deaths as of July 1, making it the most urgent active PHEIC on the planet — and a landmark treatment trial just opened enrollment this week. The overall mood is tense but forward-moving: a first-ever diagnostic test is authorized and therapeutics are finally being tested.

🦠 OUTBREAKS & VIRUSES

EBOLA BUNDIBUGYO VIRUS — DRC AND UGANDA (PHEIC)

  • As of July 1, 2026, a cumulative 1,460 confirmed cases and 452 deaths have been reported from the DRC, with cross-border transmission continuing in Uganda. [1]
  • WHO declared this outbreak a Public Health Emergency of International Concern on May 17, 2026; the IHR Emergency Committee confirmed the PHEIC does not yet meet criteria for a pandemic emergency. [2] [3]
  • Africa CDC and WHO launched a joint continental Ebola response plan on June 5, targeting US$518 million to support African countries. [4]
  • WHO issued its first comprehensive clinical management guidelines covering all Ebola and Marburg filovirus types on June 17, 2026. [5]
  • CDC has been conducting enhanced Ebola airport screening at Washington-Dulles and Atlanta airports since late May. [6] [7]

EBOLA — NEW DIAGNOSTIC TOOL

  • On July 2, 2026, WHO added the first-ever molecular diagnostic test for Bundibugyo virus (BDBV) to its Emergency Use Listing, detecting viral genetic material in blood samples for rapid confirmation. [8]

ANDES HANTAVIRUS — M/V HONDIUS CRUISE SHIP, MULTI-COUNTRY

  • The fifth WHO Disease Outbreak News report, published July 2, 2026, provides the latest update on the Andes hantavirus (ANDV) cluster linked to cruise ship M/V Hondius, first reported May 2. [9]
  • Earlier reporting confirmed multiple laboratory-confirmed Andes hantavirus cases among passengers from 23 countries; WHO Director-General thanked the people of Tenerife for helping safely disembark over 120 passengers. [10]
  • CDC continued issuing hantavirus response transcripts through June 24, 2026, indicating the situation remains under active surveillance.

NIPAH VIRUS — INDIA (KERALA)

  • On June 11, 2026, Kerala State confirmed one laboratory-confirmed Nipah virus (NiV) case in Kozhikode district — an adult male who developed neurological symptoms on May 30 and was hospitalized June 10.
  • This follows two earlier NiV cases in West Bengal healthcare workers confirmed January 30, 2026, and a Bangladesh case confirmed February 6, 2026.

WEST NILE VIRUS — UNITED STATES

  • CDC warned on July 1, 2026 of an early and record-setting West Nile virus season heading into America's 250th Independence Day weekend, urging mosquito bite prevention measures nationally.

MPOX — RECOMBINANT STRAIN

  • WHO reported in February 2026 two cases of a recombinant mpox strain combining genomic elements of both clade Ib and clade IIb MPXV — a natural but monitored viral recombination event.

MEASLES — BANGLADESH AND GLOBAL

  • Bangladesh notified WHO on April 4, 2026 of 19,161 suspected measles cases and 2,897 laboratory-confirmed cases across 58 of 64 districts nationally.
  • Global measles cases surged to 10.3 million infections in 2023 per prior CDC data, underlining the ongoing vaccination gap driving current surges.

AVIAN INFLUENZA A(H9N2) — ITALY

  • Italy confirmed one human case of avian influenza A(H9N2) in an adult male returning from Senegal, reported to WHO March 21, 2026, with next-generation sequencing confirming the subtype.

YELLOW FEVER — GLOBAL

  • From January 1 to May 26, 2026, six countries reported 79 human yellow fever infections; transmission in the Americas continued from a 2025 surge into 2026.

SALMONELLA — MULTIPLE ACTIVE U.S. OUTBREAKS

  • CDC is tracking a Salmonella outbreak linked to backyard poultry in 13 states (34 people sick as of April 23, 2026), now expanded with 150 additional cases, over a quarter in children under 5.
  • CDC also warns of a Salmonella outbreak linked to whole cucumbers (May 20, 2026) and a separate outbreak linked to eggs (June 7, 2026).
  • An extensively drug-resistant Salmonella outbreak linked to moringa powder capsules has hospitalized three people across multiple states.

LISTERIA — ACTIVE U.S. OUTBREAKS

  • CDC warns of Listeria outbreak linked to requesón/soft ricotta cheese as of June 5, 2026.
  • A separate Listeria outbreak linked to prepared meals (expanded in September–October 2025) continues with CDC urging consumers to check refrigerators for recalled foods.

INFANT BOTULISM — FORMULA RECALL

  • CDC updated its infant botulism outbreak response on June 13, 2026, urging parents to immediately stop using all Nara Organics Whole Milk Organic Infant Formula linked to confirmed cases.

NEW WORLD SCREWWORM — U.S. RESPONSE

  • CDC activated its Emergency Operations Center on June 12, 2026 for a New World Screwworm response, a parasitic fly whose larvae can infest living tissue of mammals including humans.

DRUG-RESISTANT BACTERIA

  • A CDC report from September 23, 2025 found a dramatic increase in dangerous drug-resistant bacteria across the United States, underscoring the ongoing antimicrobial resistance threat.

🧬 LONGEVITY & AGING

SENESCENCE AND BONE REPAIR — NAD+ PATHWAY

  • A study published in Bioactive Materials (June 27, 2026) describes a hierarchical scaffold engineered to modulate senescent cell metabolism, restoring NAD+ homeostasis and redox balance to improve aged bone repair in preclinical models.
  • NAD+ depletion is a hallmark of cellular aging; restoring it in bone tissue addresses a key mechanism behind impaired fracture healing in older adults.

DEDIFFERENTIATION VERSUS SENESCENCE — CARTILAGE CELLS

  • Researchers (Regen Ther, June 13, 2026) studying long-term expandable auricular chondrocytes identified a conserved nine-gene decline module that drives dedifferentiation independently of classical cellular senescence.
  • The finding suggests cartilage aging and loss of cell identity can occur through a senescence-independent pathway, opening new therapeutic angles for cartilage regeneration.

KAEMPFEROL FROM MORINGA AND LONGEVITY — DROSOPHILA MODEL

  • A Toxicology Reports study (June 25, 2026) found that kaempferol isolated from Moringa oleifera increased lifespan and reduced efavirenz-induced functional senescence in Drosophila melanogaster.
  • Efavirenz is an antiretroviral drug; the finding hints kaempferol may partially counteract drug-accelerated aging at the cellular level — though Drosophila results require validation in mammals.

INSULIN RESISTANCE AND COGNITIVE DECLINE IN AGING

  • A Scandinavian Journal of Primary Health Care study (June 23, 2026) found associations between insulin resistance and reduced health-related quality of life alongside mild cognitive impairment during aging.
  • The link reinforces the growing geroscience view that metabolic dysfunction and brain aging are mechanistically intertwined.

DELIRIUM AS A BRIDGE BETWEEN INFECTION AND DEMENTIA

  • Two commentaries in Lancet Healthy Longevity (Sipilä & Kivimäki; Penfold et al.) propose that delirium during severe infections may be a direct mechanistic link driving subsequent dementia in older patients.
  • The hypothesis: acute infection triggers neuroinflammation, manifesting as delirium, which leaves residual neurological damage accelerating dementia progression.

MULTIPLE LONG-TERM CONDITIONS AND KIDNEY DISEASE MORTALITY

  • The NURTuRE-CKD multicentre cohort study (Annals of Medicine, June 23, 2026) found that accumulating multiple long-term conditions substantially worsens mortality, progression to kidney failure, and quality of life in CKD patients.

METFORMIN AND AGING — ONGOING TRIAL

  • The Antecedent Metabolic Health and Metformin Aging Study (NCT04264897) remains active on ClinicalTrials.gov, testing whether the anti-diabetic drug metformin can slow aging and prolong healthspan, with investigators hypothesizing metabolic health history modifies the drug's geroprotective effect.

💊 NEW CURES & APPROVALS

LUMVOA (VELIGROTUG-VVZE) — VIRIDIAN THERAPEUTICS INC

  • Viridian Therapeutics received an original FDA approval (ORIG AP, BLA761530) for LUMVOA, whose active ingredient veligrotug-vvze represents a new biological entity; indication details align with Viridian's pipeline focus on thyroid eye disease (TED).

ROMVIMZA (VIMSELTINIB) — DECIPHERA PHARMACEUTICALS

  • Deciphera Pharma received a supplemental approval (SUPPL AP, NDA219304) for ROMVIMZA (vimseltinib), a CSF1R kinase inhibitor targeting tenosynovial giant cell tumor.

BESREMI (ROPEGINTERFERON ALFA-2B-NJFT) — PHARMAESSENTIA CORP

  • PharmaEssentia received a supplemental approval (SUPPL AP, BLA761166) for BESREMI, a long-acting interferon alfa used for polycythemia vera.

SARCLISA (ISATUXIMAB-IRFC) — SANOFI AVENTIS US

  • Sanofi received a supplemental approval (SUPPL AP, BLA761113) for SARCLISA, an anti-CD38 monoclonal antibody indicated for multiple myeloma.

SKYRIZI (RISANKIZUMAB-RZAA) — ABBVIE INC

  • AbbVie received two supplemental approvals (SUPPL AP, BLA761105 and BLA761262) for SKYRIZI, an IL-23 inhibitor used in plaque psoriasis, psoriatic arthritis, and Crohn's disease.

RINVOQ LQ (UPADACITINIB) — ABBVIE

  • AbbVie received a supplemental approval (SUPPL AP, NDA218347) for RINVOQ LQ, a JAK1 inhibitor used across multiple inflammatory indications including rheumatoid arthritis and atopic dermatitis.

ZEVTERA (CEFTOBIPROLE MEDOCARIL SODIUM) — ISTX

  • A supplemental approval (SUPPL AP, NDA218275) was issued for ZEVTERA, a fifth-generation cephalosporin antibiotic with activity against MRSA, relevant to the growing drug-resistant bacteria threat flagged by CDC.

NOTE: openFDA records carry no stamped approval date in this batch; all are confirmed active application actions.

🧪 CLINICAL TRIALS

PARTNERS TRIAL — BUNDIBUGYO VIRUS DISEASE TREATMENTS (DRC)

  • WHO announced on July 2, 2026 that the PARTNERS clinical trial opened patient enrollment in the DRC, the first-ever scientific trial to evaluate potential treatments for Ebola disease caused by Bundibugyo virus.
  • WHO convened expert groups in May 2026 to assess candidate vaccines and therapeutics for Bundibugyo virus, generating the priority list now being tested in PARTNERS.

PDE4 PET IMAGING IN ALZHEIMER DISEASE AND MCI — NCT07169630

  • An NIH study (ClinicalTrials.gov, updated July 2, 2026) is using PET imaging to measure phosphodiesterase-4 (PDE4) levels in volunteers with Alzheimer disease or mild cognitive impairment, targeting neuroinflammation as a biomarker mechanism underlying about 5 million U.S. cases.

BRIGHT LIGHT THERAPY AND BIOLOGICAL AGE IN LUNG CANCER — NCT07064395

  • A randomized trial (updated July 2, 2026) is investigating whether bright light therapy improves sleep in lung cancer patients and, notably, whether it measurably lowers biological age as assessed by clinical biomarkers.

AMINO ACID SUPPLEMENTATION IN PARKINSON'S DISEASE — NCT07115563

  • A trial (updated July 2, 2026) is evaluating whether a tailored amino acid supplement improves nutrition, metabolic function, body composition, and physical and mental function in adults living with Parkinson's disease.

ALPHA-LIPOIC ACID PLUS MIRABEGRON FOR OBESITY — NCT05713799

  • An NIH trial (updated July 2, 2026) is testing the combination of mirabegron (a beta-3 adrenergic agonist) and alpha-lipoic acid in men and women with obesity, targeting a non-GLP-1 pharmacological approach to weight management.

AMLITELIMAB FOR ATOPIC DERMATITIS — NCT06241118

  • A Phase 3, randomized, double-blind, placebo-controlled multinational trial (updated July 2, 2026) is evaluating subcutaneous amlitelimab in participants aged 12 and older with moderate-to-severe atopic dermatitis who failed prior biologic or oral JAK inhibitor therapy.

METFORMIN AGING STUDY — NCT04264897

  • The Antecedent Metabolic Health and Metformin Aging Study (ClinicalTrials.gov, updated July 2, 2026) is actively testing metformin as a pharmaceutical candidate to slow aging and extend healthspan in adults stratified by prior metabolic health history.

MICROALGAL OMEGA-3 BIOAVAILABILITY — NCT07241377

  • A randomized, double-blind, parallel, placebo-controlled trial (updated July 2, 2026) is comparing EPA+DHA absorption from two microalgal oil formulations versus fish oil over 6 weeks in healthy adults — relevant to plant-based longevity nutrition strategies.

📢 PUBLIC HEALTH

WEST NILE EARLY SEASON WARNING — JULY 4TH HOLIDAY

  • CDC explicitly warned on July 1, 2026 that West Nile virus is showing record early-season case numbers and urged all Americans to use mosquito repellent, wear long sleeves, and eliminate standing water over the Independence Day holiday weekend.

CDC ACIP MEETING CONCLUDED — JUNE 25-26, 2025

  • The CDC Advisory Committee on Immunization Practices (ACIP) held its meeting June 25-26, 2025 and issued a joint statement; full agenda and presentations are publicly available online.

WHO FOOD SAFETY FIGURES

  • WHO released updated global food safety estimates on June 4, 2026: unsafe food causes 866 million illnesses and 1.5 million deaths annually, with children under 5 facing nearly 3 times the illness risk of older children and adults.

INFANT FORMULA CEREULIDE TOXIN — MULTI-COUNTRY RECALL

  • WHO flagged a multi-country food safety event in March 2026 involving infant formula and products contaminated with cereulide toxin via contaminated arachidonic acid (ARA) oil used as an ingredient across multiple internationally distributed brands.

CDC BIOSURVEILLANCE MILESTONE

  • CDC's Traveler-Based Genomic Surveillance program surpassed one million voluntary air travel participants as of January 30, 2026, bolstering early detection capacity for novel pathogens at U.S. ports of entry.

U.S. WHO WITHDRAWAL COMPLETED

  • The United States formally completed its withdrawal from the World Health Organization on January 22, 2026, citing COVID-19 response failures and a shift toward bilateral health agreements — a structural change affecting global outbreak coordination.

This briefing is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personal health decisions.

📎 Sources

  1. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  2. Epidemic of Ebola Disease caused by Bundibugyo virus in the De… — WHO News
  3. First meeting of the IHR Emergency Committee regarding the epi… — WHO News
  4. Africa CDC and WHO launch joint continental Ebola response plan — WHO News
  5. WHO issues comprehensive guidelines on filovirus disease, incl… — WHO News
  6. Enhanced Ebola Airport Screening Begins at Washington-Dulles I… — CDC Newsroom
  7. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom
  8. WHO adds first diagnostic test for Ebola Bundibugyo virus to i… — WHO News
  9. Hantavirus outbreak linked to cruise ship travel, Multi-locations — WHO Disease Outbreak News
  10. Follow-up message by the WHO Director-General to the people of… — WHO News

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260705-02-v18 · 2026-07-05 02:02 UTC

Read next